Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6IR3P)

• Drug Name: Liothyronine Drug Info
• Synonyms: liothyronine; 3,3',5-Triiodo-L-thyronine; 6893/2/3; Liothyronin; Tresitope; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; triothyrone; Liothyroninum; Liotironina; 3,5,3'-Triiodo-L-thyronine; L-T3; T3; 3,3',5-Triiodothyronine; Triiodo-L-thyronine; Lyothyronine; 3,5,3'TRIIODOTHYRONINE; L-3,5,3'-Triiodothyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; T3 (amino acid); T3 (Hormone); L-3,3',5-TriioDOThyronine; Liothyronine [INN:BAN]; Rathyronine; Triothyrone; THYROID HORMONE; Liothyronine I 131; Liothyronine I 131 [USAN]; T3 liothyronine; Cytomel (TN); Euthroid-1; Euthroid-2; Euthroid-3; Liothyronine (INN); Liothyroninum[INN-Latin]; Liotironina [INN-Spanish]; T3 (Triiodothyronine); T3 (VAN); Tertroxin (TN); Thyrolar-1; Thyrolar-2; Thyrolar-3; Tri-Thyrotope; Triiodothyronine (T3); Triomet-131; Euthroid-05; Thyrolar-025; Thyrolar-05; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Thyronine, 3,3',5-triiodo-, L-(6CI); L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-(9CI); 3,3'5-Triiodo-L-thyronine; 3,5,3'-Tri-iodo-L-thyronine; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine

Indication

Disease Entry	ICD 11	Status	REF
Congenital hypothyroidism		Approved	[1]
Edema	MG29	Approved	[1]
Goiter		Approved	[1]
Hypothyroidism	5A00	Approved	[2]
Thyroid cancer	2D10	Approved	[1]
Congestive heart failure	BD10	Phase 3	[3]

• Therapeutic Class: Hormone Replacement Agents
• Cross-matching ID:
  PubChem CID: 5920
  ChEBI ID: CHEMBL1544
  CAS Number: CAS 15785-49-6
  TTD Drug ID: DM6IR3P
  VARIDT Drug ID: DR00173
  INTEDE Drug ID: DR0959
  ACDINA Drug ID: D00368

Molecule-Related Drug Atlas

Drug(s) Targeting Thyroid hormone receptor alpha (THRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levothyroxine	DMHN027	Congenital hypothyroidism		Approved	[17]
Dextrothyroxine Sodium	DMBVEC7	High blood cholesterol level	5C80.00	Approved	[18]
BCT303	DMUFY4K	Hypothyroidism	5A00	Phase 2	[19]
tiratricol	DMZO6CV	Wound healing	EL8Y	Clinical trial	[20]
3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one	DM2JBQI	Discovery agent	N.A.	Investigative	[21]
3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid	DMDFHCU	Discovery agent	N.A.	Investigative	[22]
3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one	DMJYCHG	Discovery agent	N.A.	Investigative	[21]
4-(4-hexylphenyl)-4-oxobut-2-enoic acid	DMR9TBW	Discovery agent	N.A.	Investigative	[21]
(3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid	DM5GN46	Discovery agent	N.A.	Investigative	[22]
1-(4-hexylphenyl)-3-morpholinopropan-1-one	DMFN8T6	Discovery agent	N.A.	Investigative	[21]

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[23]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[24]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[26]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[25]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[27]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[28]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[29]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[30]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[27]

Drug(s) Transported By Sodium/taurocholate cotransporting polypeptide (SLC10A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[31]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[32]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[33]
Estrone sulfate	DMVBIZL	Atrophic vaginitis	GA30.2	Approved	[34]
Taurocholic Acid	DM2LZ8F	Type-2 diabetes	5A11	Phase 1/2	[35]
Sodium taurocholate	DM3GO0J	Type-2 diabetes	5A11	Phase 1/2	[36]

Drug(s) Transported By Organic anion transporting polypeptide 1A2 (SLCO1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[37]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[38]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[39]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[40]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[32]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[33]
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[41]
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[42]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[43]
Labetalol	DMK8U72	Hypertension	BA00-BA04	Approved	[44]

Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[10]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[25]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[45]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[46]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[25]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[47]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[28]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[30]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[48]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[30]

Drug(s) Transported By Organic anion transporting polypeptide 1C1 (SLCO1C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[49]
Levothyroxine	DMHN027	Congenital hypothyroidism		Approved	[49]
[3H]estradiol-17beta-glucuronide	DM3KJ45	Discovery agent	N.A.	Investigative	[50]

Drug(s) Transported By Organic anion transporting polypeptide 4A1 (SLCO4A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[51]
Estrone sulfate	DMVBIZL	Atrophic vaginitis	GA30.2	Approved	[52]
Benzylpenicillin	DMS9503	Actinomycosis		Phase 3	[51]
Taurocholic Acid	DM2LZ8F	Type-2 diabetes	5A11	Phase 1/2	[8]

Drug(s) Transported By Organic anion transporting polypeptide 4C1 (SLCO4C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Digoxin	DMQCTIH	Arrhythmia	BC9Z	Approved	[6]
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[53]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[6]
Estrone sulfate	DMVBIZL	Atrophic vaginitis	GA30.2	Approved	[54]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[55]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[56]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[57]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[58]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[60]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[61]
Metronidazole	DMTIVEN	Abscess		Approved	[62]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[63]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[64]

Drug(s) Metabolized By Sulfotransferase 1A1 (SULT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[65]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[66]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[67]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[68]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[69]
Warfarin	DMJYCVW	Atrial fibrillation	BC81.3	Approved	[70]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[71]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[72]
Benzyl alcohol	DMBVYDI	Head and body lice	1G00.0	Approved	[73]
Teicoplanin	DMAQ2LK	Bacterial infection	1A00-1C4Z	Approved	[74]

Drug(s) Affected By All-trans-retinol dehydrogenase ADH1B (ADH1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[75]
Selenium	DM25CGV	N. A.	N. A.	Approved	[76]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[77]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[81]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[82]
Flucloxacillin	DMNUWST	Bacterial infection	1A00-1C4Z	Approved	[83]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[79]

Drug(s) Affected By Alpha-enolase (ENO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[85]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[86]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[87]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[88]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[90]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[91]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[92]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[93]

Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[94]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[95]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[96]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[97]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[98]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[99]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[98]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[101]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]

Drug(s) Affected By Collagen alpha-3(VI) chain (COL6A3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[103]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[104]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[105]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[106]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[82]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[107]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[108]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]

Drug(s) Affected By Ras-related protein Rab-3B (RAB3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[111]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[112]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[106]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[114]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[116]

Drug(s) Affected By Fibroblast growth factor 7 (FGF7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[117]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[118]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[119]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[120]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[118]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[121]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[108]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[122]

Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[124]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[125]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[126]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[126]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[124]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[124]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[127]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[128]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]

Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[124]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[125]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[129]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[130]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[124]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[131]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[124]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[132]
Glibenclamide	DM8JXPZ	Diabetic complication	5A2Y	Approved	[133]

Drug(s) Affected By ATP-dependent 6-phosphofructokinase, platelet type (PFKP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[134]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[104]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[136]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[137]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]

Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[138]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[124]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[125]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[139]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[124]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[124]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[140]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[133]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[139]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[124]

Drug(s) Affected By Monocarboxylate transporter 7 (SLC16A6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[141]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[101]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[90]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[111]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[92]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]

Drug(s) Affected By Stromelysin-3 (MMP11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[145]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[146]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[147]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[148]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[137]

Drug(s) Affected By Phosphoenolpyruvate carboxykinase, cytosolic (PCK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[149]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[150]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[88]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[151]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[152]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[153]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]

Drug(s) Affected By Glucose-6-phosphatase catalytic subunit 1 (G6PC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[154]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[77]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[152]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[155]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[77]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[77]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[81]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[156]

Drug(s) Affected By 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[157]
Calcidiol	DMN4CV5	Hypophosphatemia		Approved	[158]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[159]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[160]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[161]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[162]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[163]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]

Drug(s) Affected By Organic solute transporter subunit beta (SLC51B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[165]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[149]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[166]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[88]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[167]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[166]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[168]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[145]

Drug(s) Affected By Transcriptional and immune response regulator (TCIM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[169]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[170]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[164]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[171]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[172]

Drug(s) Affected By Thyroid hormone-inducible hepatic protein (THRSP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[77]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[77]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[77]
Clopidogrel	DMOL54H	Acute coronary syndrome	BA41	Approved	[173]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Mitotane	DMU1GX0	Adrenocortical carcinoma	2D11.Z	Approved	[173]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[174]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[79]

Drug(s) Affected By Uncharacterized protein C20orf204 (C20ORF204)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[79]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]

Drug(s) Affected By Meiosis-specific coiled-coil domain-containing protein MEIOC (MEIOC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[177]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[104]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[178]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[179]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[104]

Drug(s) Affected By LYR motif-containing protein 9 (LYRM9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[146]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[137]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[181]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[182]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[183]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[184]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]

Drug(s) Affected By Serine/threonine-protein kinase Chk1 (CHEK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[185]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[129]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[186]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[187]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[188]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[190]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[191]
Olaparib	DM8QB1D	Ovarian cancer	2C73	Approved	[192]

Drug(s) Affected By Apolipoprotein L1 (APOL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[193]
Selenium	DM25CGV	N. A.	N. A.	Approved	[76]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[164]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[145]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Bortezomib	DMNO38U	Leukemia		Approved	[194]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[174]

Drug(s) Affected By Proepiregulin (EREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[185]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[195]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[149]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[195]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[195]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[196]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[197]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[195]

Drug(s) Affected By Serine palmitoyltransferase 2 (SPTLC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[198]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[199]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[132]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[200]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[201]

Drug(s) Affected By Disintegrin and metalloproteinase domain-containing protein 12 (ADAM12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[119]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[104]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[172]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[202]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[203]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[204]
Chlorothiazide	DMLHESP	Chronic heart failure	BD1Z	Approved	[205]

Drug(s) Affected By Cytoplasmic dynein 1 light intermediate chain 2 (DYNC1LI2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[206]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[97]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[149]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[208]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[207]

Drug(s) Affected By Trans-Golgi network integral membrane protein 2 (TGOLN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[14]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[206]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[145]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[209]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[14]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[210]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]

Drug(s) Affected By Lysine-specific demethylase hairless (HR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[200]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[146]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[211]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[212]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[213]

Drug(s) Affected By Plexin-C1 (PLXNC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[104]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[170]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[214]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[215]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]

Drug(s) Affected By TAF5-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 5L (TAF5L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[76]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[145]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[178]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[216]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[217]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[218]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[219]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[220]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[221]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[221]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[81]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[220]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[221]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[222]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[220]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[223]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[220]

Drug(s) Affected By Echinoderm microtubule-associated protein-like 2 (EML2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[76]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[136]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[146]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[224]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[76]

Drug(s) Affected By Albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[174]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[225]
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[226]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[227]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[228]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[229]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[230]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[231]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[232]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[233]

Drug(s) Affected By Antileukoproteinase (SLPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[195]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[195]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[149]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[195]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[195]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[195]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[195]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Penbutolol	DM4ES8F	Hypertension	BA00-BA04	Approved	[195]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[195]

Drug(s) Affected By Amyloid-beta precursor protein (APP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Selenium	DM25CGV	N. A.	N. A.	Approved	[76]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[150]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[234]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[235]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[236]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[237]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Aluminium	DM6ECN9	Hyperhidrosis	EE00	Approved	[238]

Drug(s) Affected By Thyroxine-binding globulin (SERPINA7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Leuprolide	DM5XPIJ	Plasma cell myeloma	2A83.1	Approved	[225]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[239]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[240]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[241]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[79]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[242]

Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[243]
Bambuterol	DMKLSHF	Asthma	CA23	Approved	[244]
Terbutaline	DMD4381	Asthma	CA23	Approved	[245]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[246]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[247]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[248]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[249]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[250]

Drug(s) Affected By Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[149]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[118]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[111]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[251]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[252]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[253]

Drug(s) Affected By Histone H2A type 1 (H2AC11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[193]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[103]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[254]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[164]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[216]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[217]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[255]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[256]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[257]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[165]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[258]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[259]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[195]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[260]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[261]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[195]

Drug(s) Affected By C-C motif chemokine 5 (CCL5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[262]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[263]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[264]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[150]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[265]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[266]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[267]
Emetine	DMCT2YF	Hepatitis virus infection	1E50-1E51	Approved	[268]

Drug(s) Affected By Replication protein A 32 kDa subunit (RPA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[185]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[269]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Quizartinib	DM8Y4JS	Acute myeloid leukaemia	2A60	Approved	[270]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[164]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]

Drug(s) Affected By Histone H2AX (H2AX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[271]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[272]
Selenium	DM25CGV	N. A.	N. A.	Approved	[76]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[273]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[269]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[274]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[275]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[276]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[277]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[278]

Drug(s) Affected By Histone H1.5 (H1-5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[193]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[279]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[280]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[281]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[254]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[164]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[282]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]

Drug(s) Affected By Integrin beta-5 (ITGB5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[144]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[14]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[104]
Propylthiouracil	DM6D7N8	Hyperthyroidism	5A02	Approved	[14]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[104]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[283]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[14]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[284]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[285]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[286]
Methysergide	DM1EF73	Migraine	8A80	Approved	[222]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[287]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[222]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[88]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[288]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[289]

Drug(s) Affected By Heterogeneous nuclear ribonucleoprotein H3 (HNRNPH3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[99]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[87]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[290]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[291]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[292]

Drug(s) Affected By Beta-adducin (ADD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[293]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[294]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[295]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[296]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[117]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[262]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[297]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[298]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[129]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[299]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[300]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[301]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[302]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[303]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[304]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[300]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[305]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[306]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[307]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[308]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[309]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[310]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[311]

Drug(s) Affected By Inactive serine/threonine-protein kinase 19 (STK19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[312]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[106]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[313]

Drug(s) Affected By Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[314]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[150]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[88]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[288]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[315]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[316]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]

Drug(s) Affected By Peroxisomal targeting signal 1 receptor (PEX5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[241]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[212]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[76]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[317]

Drug(s) Affected By Protein HIRA (HIRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[145]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[217]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[318]
Tamibarotene	DM3G74J	T-cell leukaemia	2A90	Phase 3	[207]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[179]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[319]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[206]

Drug(s) Affected By Hydroxymethylglutaryl-CoA synthase, mitochondrial (HMGCS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[320]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[77]
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[321]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[149]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[241]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[79]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[322]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[323]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[213]

Drug(s) Affected By A-kinase anchor protein 12 (AKAP12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[160]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[77]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[161]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[104]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[324]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[200]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]

Drug(s) Affected By Dual specificity protein phosphatase 2 (DUSP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[149]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[150]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[325]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[216]
Epanova	DMHEAGL	Hypertriglyceridemia	5C80.1	Approved	[326]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[215]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[327]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 9 (TNFRSF9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[198]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[150]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[328]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[329]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[216]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[330]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[331]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[106]

Drug(s) Affected By Bcl-2-like protein 1 (BCL2L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[332]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[333]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[334]
Selenium	DM25CGV	N. A.	N. A.	Approved	[76]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[335]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[196]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[336]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[337]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[187]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[338]

Drug(s) Affected By Pregnancy-specific beta-1-glycoprotein 7 (PSG7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lucanthone	DMZLBUO	Solid tumour/cancer	2A00-2F9Z	Approved	[339]
Seocalcitol	DMKL9QO	Rickets	5B57	Phase 3	[252]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[340]

Drug(s) Affected By TNF receptor-associated factor 1 (TRAF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[341]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[280]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[214]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[216]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[342]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[330]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[343]

Drug(s) Affected By Disintegrin and metalloproteinase domain-containing protein 15 (ADAM15)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[119]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[106]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[211]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[344]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[345]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[204]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[344]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]

Drug(s) Affected By Krueppel-like factor 9 (KLF9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[346]
Selenium	DM25CGV	N. A.	N. A.	Approved	[76]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[14]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[347]
Propylthiouracil	DM6D7N8	Hyperthyroidism	5A02	Approved	[14]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[348]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]

Drug(s) Affected By kinase isozyme 4, mitochondrial (PDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[119]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[349]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[350]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[92]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[92]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[92]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[209]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[77]

Drug(s) Affected By Tigger transposable element-derived protein 6 (TIGD6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[291]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[217]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[213]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[351]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[352]

Drug(s) Affected By Transmembrane protein 44 (TMEM44)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[106]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[82]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[284]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[284]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[79]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[179]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[353]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[294]

Drug(s) Affected By Akirin-2 (AKIRIN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[315]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[132]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[110]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[194]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[106]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[292]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[174]

Drug(s) Affected By Protein FAM171B (FAM171B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[112]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[283]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[137]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[213]
OTX-015	DMI8RG1	Acute myeloid leukaemia	2A60	Phase 1/2	[354]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[355]
Mivebresib	DMCPF90	Acute myeloid leukaemia	2A60	Phase 1	[354]

Drug(s) Affected By Protein FAM83H (FAM83H)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[214]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[174]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[213]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[352]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[206]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[206]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[356]

Drug(s) Affected By Butyrophilin subfamily 2 member A1 (BTN2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[213]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[110]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[216]

Drug(s) Affected By Mesoderm induction early response protein 3 (MIER3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[171]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[206]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[357]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[295]

Drug(s) Affected By Tripartite motif-containing protein 46 (TRIM46)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[211]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[183]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[358]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
uric acid	DMA1MKT	Discovery agent	N.A.	Investigative	[359]

Drug(s) Affected By Retrotransposon-derived protein PEG10 (PEG10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[77]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[161]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[132]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[360]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[361]

Drug(s) Affected By Rho guanine nucleotide exchange factor 25 (ARHGEF25)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[137]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]

Drug(s) Affected By Condensin-2 complex subunit G2 (NCAPG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[280]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[164]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[362]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[282]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[240]

Drug(s) Affected By Coiled-coil domain-containing protein 71 (CCDC71)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[291]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[213]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[352]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[206]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[363]

Drug(s) Affected By Iron-sulfur cluster co-chaperone protein HscB (HSCB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[215]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[292]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[179]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[352]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[313]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[216]

Drug(s) Affected By Abnormal spindle-like microcephaly-associated protein (ASPM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[280]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[189]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[102]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[364]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[164]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]

Drug(s) Affected By EF-hand calcium-binding domain-containing protein 4A (CRACR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[141]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[171]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[106]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[365]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[204]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[213]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[79]

Drug(s) Affected By EF-hand calcium-binding domain-containing protein 3 (EFCAB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[137]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[366]

Drug(s) Affected By Inactive phospholipase D5 (PLD5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[177]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[143]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[283]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[241]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[79]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[179]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[204]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[104]

Drug(s) Affected By Acyl-CoA-binding domain-containing protein 4 (ACBD4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[164]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[194]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[211]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[213]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
Sulforaphane	DMQY3L0	Skin disease	EA00-EM0Z	Investigative	[367]

Drug(s) Affected By Bcl2-associated agonist of cell death (BAD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[368]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[369]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[370]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[371]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[372]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[373]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[88]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[374]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[375]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[376]

Drug(s) Affected By Peptidyl-prolyl cis-trans isomerase FKBP10 (FKBP10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[103]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[217]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[377]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[179]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[352]

Drug(s) Affected By Rho-related GTP-binding protein RhoV (RHOV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[193]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[196]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[283]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[211]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[204]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[213]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[134]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[340]

Drug(s) Affected By Msx2-interacting protein (SPEN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[76]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[348]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[209]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[295]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[378]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[292]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[137]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]

Drug(s) Affected By PTB domain-containing engulfment adapter protein 1 (GULP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[134]
Selenium	DM25CGV	N. A.	N. A.	Approved	[76]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[14]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[312]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[379]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[172]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[106]

Drug(s) Affected By LIM/homeobox protein Lhx3 (LHX3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[198]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[194]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[176]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[380]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[381]

Drug(s) Affected By Protein mono-ADP-ribosyltransferase PARP4 (PARP4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[99]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[78]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[113]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[115]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[174]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[382]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[383]
Lithium	DMZ3OU6	Bipolar disorder	6A60	Phase 2	[384]

Drug(s) Affected By Ras-related protein Rab-23 (RAB23)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[164]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[145]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[112]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[194]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[284]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[292]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[241]

Drug(s) Affected By Sulfotransferase 4A1 (SULT4A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[365]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[204]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[385]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[386]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[180]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[352]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[295]
Mononitrophenol	DM4QO9G	N. A.	N. A.	Investigative	[385]
L-thyroxine	DM83HWL	N. A.	N. A.	Investigative	[385]

Drug(s) Affected By Thyrotropin subunit beta (TSHB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[387]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Octreotide	DMHIDCJ	Acromegaly	5A60.0	Approved	[388]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[389]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[390]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[391]
NITRATE	DMVFB93	Discovery agent	N.A.	Investigative	[392]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[393]

Drug(s) Affected By Type I iodothyronine deiodinase (DIO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[394]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[110]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[395]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[178]
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[396]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[397]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[396]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[240]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[398]

Drug(s) Affected By Monocarboxylate transporter 8 (SLC16A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[142]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[101]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[291]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[146]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[123]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[242]
DTI-015	DMXZRW0	Brain cancer	2A00	Approved	[345]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[399]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thyroid hormone receptor alpha (THRA)	TTTSEPU	THA_HUMAN	Antagonist	[4]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1C1 (SLCO1C1)	DTPYCQ4	SO1C1_HUMAN	Substrate	[5]
Organic anion transporting polypeptide 4A1 (SLCO4A1)	DT8H2IC	SO4A1_HUMAN	Substrate	[6]
Organic anion transporting polypeptide 4C1 (SLCO4C1)	DTY0QMU	SO4C1_HUMAN	Substrate	[6]
Sodium/taurocholate cotransporting polypeptide (SLC10A1)	DT56EKP	NTCP_HUMAN	Substrate	[7]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[8]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[9]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[11]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Substrate	[12]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Gene/Protein Processing	[13]
A-kinase anchor protein 12 (AKAP12)	OTCVRDDX	AKA12_HUMAN	Gene/Protein Processing	[14]
Abnormal spindle-like microcephaly-associated protein (ASPM)	OTKXQMNA	ASPM_HUMAN	Gene/Protein Processing	[14]
Acyl-CoA-binding domain-containing protein 4 (ACBD4)	OTVR7MLK	ACBD4_HUMAN	Gene/Protein Processing	[14]
Akirin-2 (AKIRIN2)	OTQ6WSKW	AKIR2_HUMAN	Gene/Protein Processing	[14]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[15]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[16]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[16]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[16]
All-trans-retinol dehydrogenase ADH1B (ADH1B)	OTV3TB81	ADH1B_HUMAN	Gene/Protein Processing	[16]

References

• [1] Liothyronine FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] ClinicalTrials.gov (NCT00790738) Liothyronine (T3) for Bipolar Depression. U.S. National Institutes of Health.
• [4] Evaluation of thyroid hormone action in a case of generalized resistance to thyroid hormone with chronic thyroiditis: discovery of a novel heterozy... Endocr J. 2007 Dec;54(5):727-32.
• [5] Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004 Sep;145(9):4384-91.
• [6] Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74.
• [7] Identification of thyroid hormone transporters. Biochem Biophys Res Commun. 1999 Jan 19;254(2):497-501.
• [8] Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
• [9] Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 1999 Jun 11;274(24):17159-63.
• [10] LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
• [11] FDA Label of Liothyronine sodium. The 2020 official website of the U.S. Food and Drug Administration.
• [12] Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
• [13] Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol. 2011 Oct 21;6(10):1096-106.
• [14] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [15] In vitro fluorescence displacement investigation of thyroxine transport disruption by bisphenol A. J Environ Sci (China). 2011;23(2):315-21. doi: 10.1016/s1001-0742(10)60408-1.
• [16] Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
• [17] Thyroid hormone resistance and pituitary enlargement after thyroid ablation in a woman on levothyroxine treatment. Thyroid. 2008 Oct;18(10):1119-23.
• [18] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [19] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [20] Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34.
• [21] Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80.
• [22] Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7.
• [23] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [24] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [25] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [26] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [27] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [28] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [29] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [30] FDA Drug Development and Drug Interactions
• [31] Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34.
• [32] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [33] Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
• [34] Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem. 2004 Feb 20;279(8):7213-22.
• [35] Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther. 1999 Dec;291(3):1204-9.
• [36] Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther. 2007 Jun;321(3):1170-8.
• [37] Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
• [38] Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
• [39] Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
• [40] Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
• [41] Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
• [42] Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
• [43] Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
• [44] Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39.
• [45] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [46] Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
• [47] Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
• [48] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [49] Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96.
• [50] The blood-brain barrier thyroxine transporter organic anion-transporting polypeptide 1c1 displays atypical transport kinetics. Endocrinology. 2009 Nov;150(11):5153-62.
• [51] Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
• [52] Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J Pharmacol Exp Ther. 2004 Dec;311(3):1032-7.
• [53] Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14.
• [54] Transport of estrone 3-sulfate mediated by organic anion transporter OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin in OATP4C1. Drug Metab Pharmacokinet. 2010;25(3):314-7.
• [55] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [56] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [57] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [58] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [59] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [60] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [61] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [62] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [63] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [64] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [65] Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
• [66] Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
• [67] Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
• [68] Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
• [69] Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
• [70] Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
• [71] Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
• [72] Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
• [73] Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
• [74] The 2.7 A resolution structure of the glycopeptide sulfotransferase Teg14. Acta Crystallogr D Biol Crystallogr. 2010 Dec;66(Pt 12):1278-86.
• [75] Differences in the activities of resveratrol and ascorbic acid in protection of ethanol-induced oxidative DNA damage in human peripheral lymphocytes. Food Chem Toxicol. 2012 Feb;50(2):168-74.
• [76] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [77] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [78] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [79] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [80] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [81] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [82] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [83] Identification of flucloxacillin-modified hepatocellular proteins: implications in flucloxacillin-induced liver injury. Toxicol Sci. 2023 Mar 20;192(1):106-116. doi: 10.1093/toxsci/kfad015.
• [84] Oxidative modifications of proteins by sodium arsenite in human umbilical vein endothelial cells. Environ Toxicol. 2011 Oct;26(5):459-71. doi: 10.1002/tox.20572. Epub 2010 Mar 1.
• [85] Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. Toxicol Lett. 2017 Nov 5;281:26-34. doi: 10.1016/j.toxlet.2017.09.001. Epub 2017 Sep 5.
• [86] Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
• [87] Differential protein expression of peroxiredoxin I and II by benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate cell lines. Toxicol Appl Pharmacol. 2007 Apr 15;220(2):197-210. doi: 10.1016/j.taap.2006.12.030. Epub 2007 Jan 9.
• [88] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [89] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [90] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [91] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [92] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [93] Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 2011 Mar;120(1):109-22.
• [94] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [95] Insulin regulation of hexose transport in mouse 3T3-L1 cells expressing the human HepG2 glucose transporter. J Biol Chem. 1990 Nov 25;265(33):20106-16.
• [96] Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun. 2001 Jan 26;280(3):664-74. doi: 10.1006/bbrc.2000.4216.
• [97] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [98] Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. Toxicol Lett. 2009 Jan 30;184(2):81-4. doi: 10.1016/j.toxlet.2008.10.017. Epub 2008 Oct 28.
• [99] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [100] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [101] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [102] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [103] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [104] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [105] Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound. Toxicol In Vitro. 2021 Jun;73:105112. doi: 10.1016/j.tiv.2021.105112. Epub 2021 Feb 22.
• [106] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [107] Increased expression of type VI collagen genes in drug-induced gingival enlargement. FEBS Lett. 1993 Nov 8;334(1):65-8. doi: 10.1016/0014-5793(93)81681-o.
• [108] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [109] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [110] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [111] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [112] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [113] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [114] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [115] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [116] Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011 Apr;84(4):801-15.
• [117] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [118] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [119] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [120] Regulation of keratinocyte growth factor and scatter factor in cyclosporin-induced gingival overgrowth. J Oral Pathol Med. 2004 Aug;33(7):391-7. doi: 10.1111/j.1600-0714.2004.00223.x.
• [121] Keratinocyte growth factor is upregulated by the hyperplasia-inducing drug nifedipine. Cytokine. 2000 Oct;12(10):1566-9. doi: 10.1006/cyto.2000.0756.
• [122] Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21737-42. doi: 10.1073/pnas.1007863107. Epub 2010 Nov 22.
• [123] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [124] Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
• [125] Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
• [126] Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
• [127] In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
• [128] AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
• [129] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [130] A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
• [131] Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
• [132] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [133] Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
• [134] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [135] Hypoxia-inducible factor-1 (HIF-1) pathway activation by quercetin in human lens epithelial cells. Exp Eye Res. 2009 Dec;89(6):995-1002. doi: 10.1016/j.exer.2009.08.011. Epub 2009 Sep 1.
• [136] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [137] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [138] Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
• [139] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [140] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [141] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [142] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [143] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [144] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [145] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [146] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [147] Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mullerian duct cells using microarray. Cancer Lett. 2005 Apr 8;220(2):197-210.
• [148] Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr. 2010 Jul;47(1):81-90.
• [149] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [150] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [151] Adipogenic Effects and Gene Expression Profiling of Firemaster? 550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013. doi: 10.1289/EHP1318.
• [152] Expression dynamics of pregnane X receptor-controlled genes in 3D primary human hepatocyte spheroids. Arch Toxicol. 2022 Jan;96(1):195-210. doi: 10.1007/s00204-021-03177-y. Epub 2021 Oct 23.
• [153] Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med. 2021 Feb;11(2):e335. doi: 10.1002/ctm2.335.
• [154] Downregulation of glucose-6-phosphatase expression contributes to fluoxetine-induced hepatic steatosis. J Appl Toxicol. 2021 Aug;41(8):1232-1240. doi: 10.1002/jat.4109. Epub 2020 Nov 12.
• [155] Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front Pharmacol. 2018 Oct 11;9:993.
• [156] Withaferin A: A potential selective glucocorticoid receptor modulator with anti-inflammatory effect. Food Chem Toxicol. 2023 Sep;179:113949. doi: 10.1016/j.fct.2023.113949. Epub 2023 Jul 17.
• [157] DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics. 2004 Apr 13;17(2):122-9. doi: 10.1152/physiolgenomics.00002.2003.
• [158] Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1973-81. doi: 10.1016/j.bbrc.2005.10.178. Epub 2005 Nov 7.
• [159] Actions of Vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995 Jan;136(1):20-6.
• [160] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [161] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [162] Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005 Jan;115(1):177-86.
• [163] 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res. 2005 Mar 15;65(6):2488-97.
• [164] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [165] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [166] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [167] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [168] Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. Biopharm Drug Dispos. 2009 Jul;30(5):241-58.
• [169] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [170] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [171] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [172] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [173] Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3. Arch Toxicol. 2019 Aug;93(8):2247-2264. doi: 10.1007/s00204-019-02495-6. Epub 2019 Jul 16.
• [174] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [175] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [176] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [177] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [178] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [179] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [180] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [181] Identification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells. Toxicol Sci. 2016 May;151(1):10-22. doi: 10.1093/toxsci/kfw032. Epub 2016 Mar 22.
• [182] Anti-proliferative and gene expression actions of resveratrol in breast cancer cells in vitro. Oncotarget. 2014 Dec 30;5(24):12891-907.
• [183] Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 2017 Nov;6(11):2646-2659. doi: 10.1002/cam4.1179. Epub 2017 Sep 27.
• [184] Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013 Mar;3(3):308-23.
• [185] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [186] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [187] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [188] Involvement of the activation of Nrf2/HO-1, p38 MAPK signaling pathways and endoplasmic reticulum stress in furazolidone induced cytotoxicity and S phase arrest in human hepatocyte L02 cells: modulation of curcumin. Toxicol Mech Methods. 2017 Mar;27(3):165-172. doi: 10.1080/15376516.2016.1273424. Epub 2017 Jan 8.
• [189] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [190] Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol Sci. 2009 Sep;111(1):120-30. doi: 10.1093/toxsci/kfp136. Epub 2009 Jun 18.
• [191] ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis. J Biol Chem. 2006 Sep 29;281(39):28764-71. doi: 10.1074/jbc.M604392200. Epub 2006 Aug 3.
• [192] PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma. PLoS One. 2014 Dec 22;9(12):e114583. doi: 10.1371/journal.pone.0114583. eCollection 2014.
• [193] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [194] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [195] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [196] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [197] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [198] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [199] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [200] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [201] Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569.
• [202] Ultradian cortisol pulsatility encodes a distinct, biologically important signal. PLoS One. 2011 Jan 18;6(1):e15766.
• [203] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.
• [204] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [205] Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. Pharmacogenomics J. 2014 Feb;14(1):35-40. doi: 10.1038/tpj.2013.3. Epub 2013 Feb 12.
• [206] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [207] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [208] Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
• [209] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [210] Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14(8):1435-1455. doi: 10.1080/15548627.2018.1474314. Epub 2018 Jul 20.
• [211] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [212] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [213] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [214] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [215] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [216] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [217] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [218] Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014 Apr 23;14:283.
• [219] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [220] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [221] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [222] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [223] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [224] Association of Arsenic Exposure with Whole Blood DNA Methylation: An Epigenome-Wide Study of Bangladeshi Adults. Environ Health Perspect. 2019 May;127(5):57011. doi: 10.1289/EHP3849. Epub 2019 May 28.
• [225] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [226] A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
• [227] The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
• [228] Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
• [229] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [230] Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
• [231] [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
• [232] Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
• [233] Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
• [234] Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007 Apr;101(1):77-86. doi: 10.1111/j.1471-4159.2006.04375.x. Epub 2007 Jan 4.
• [235] Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. J Struct Biol. 2000 Jun;130(2-3):209-16. doi: 10.1006/jsbi.2000.4285.
• [236] Increased processing of APLP2 and APP with concomitant formation of APP intracellular domains in BDNF and retinoic acid-differentiated human neuroblastoma cells. J Neurochem. 2005 Nov;95(4):1059-68. doi: 10.1111/j.1471-4159.2005.03440.x. Epub 2005 Sep 7.
• [237] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [238] Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J Alzheimers Dis. 2005 Nov;8(2):117-27; discussion 209-15. doi: 10.3233/jad-2005-8204.
• [239] Thyroid function and plasma concentrations of polyhalogenated compounds in Inuit adults. Environ Health Perspect. 2009 Sep;117(9):1380-6. doi: 10.1289/ehp.0900633. Epub 2009 May 12.
• [240] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [241] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [242] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [243] Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
• [244] Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
• [245] Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
• [246] beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
• [247] Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
• [248] Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
• [249] Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
• [250] Expression of inwardly rectifying potassium channels (GIRKs) and beta-adrenergic regulation of breast cancer cell lines. BMC Cancer. 2004 Dec 16;4:93. doi: 10.1186/1471-2407-4-93.
• [251] Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):45-56. doi: 10.1007/s13539-011-0021-y. Epub 2011 Feb 26.
• [252] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
• [253] Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 2012 Dec;64(12):3856-66. doi: 10.1002/art.37691.
• [254] In vitro effects of aldehydes present in tobacco smoke on gene expression in human lung alveolar epithelial cells. Toxicol In Vitro. 2013 Apr;27(3):1072-81.
• [255] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [256] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [257] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [258] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [259] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [260] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [261] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [262] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [263] A copper-hydrogen peroxide redox system induces dityrosine cross-links and chemokine oligomerisation. Cytokine. 2011 Dec;56(3):669-75. doi: 10.1016/j.cyto.2011.08.025. Epub 2011 Oct 1.
• [264] Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
• [265] Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia. Transplant Proc. 2006 Nov;38(9):2899-904. doi: 10.1016/j.transproceed.2006.08.136.
• [266] 13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. Am J Pathol. 2005 Jul;167(1):285-98. doi: 10.1016/S0002-9440(10)62973-2.
• [267] Identification of human cell responses to benzene and benzene metabolites. Genomics. 2007 Sep;90(3):324-33.
• [268] Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
• [269] Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem. 2007 Jul 15;15(14):4863-75. doi: 10.1016/j.bmc.2007.04.057. Epub 2007 May 3.
• [270] Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3. Arch Toxicol. 2022 Jan;96(1):177-193. doi: 10.1007/s00204-021-03174-1. Epub 2021 Oct 19.
• [271] Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget. 2016 Nov 22;7(47):77543-77557. doi: 10.18632/oncotarget.12721.
• [272] Hsa-let-7g miRNA regulates the anti-tumor effects of gastric cancer cells under oxidative stress through the expression of DDR genes. J Toxicol Sci. 2015 Jun;40(3):329-38. doi: 10.2131/jts.40.329.
• [273] Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicity. Toxicology. 2020 Apr 15;435:152422. doi: 10.1016/j.tox.2020.152422. Epub 2020 Feb 26.
• [274] Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol. 2011 Feb 15;81(4):510-7. doi: 10.1016/j.bcp.2010.11.014. Epub 2010 Nov 27.
• [275] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [276] Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010 Nov;89(11):1115-24. doi: 10.1007/s00277-010-0988-z. Epub 2010 May 25.
• [277] The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
• [278] The isoflavonoids genistein and quercetin activate different stress signaling pathways as shown by analysis of site-specific phosphorylation of ATM, p53 and histone H2AX. DNA Repair (Amst). 2004 Mar 4;3(3):235-44. doi: 10.1016/j.dnarep.2003.10.014.
• [279] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [280] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [281] Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
• [282] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [283] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [284] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [285] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [286] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [287] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [288] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [289] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [290] Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells: proteomic characterization. Exp Cell Res. 2007 Jan 15;313(2):357-68. doi: 10.1016/j.yexcr.2006.10.016. Epub 2006 Oct 25.
• [291] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [292] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [293] Genome-wide transcriptional and functional analysis of human T lymphocytes treated with benzo[alpha]pyrene. Int J Mol Sci. 2018 Nov 17;19(11).
• [294] Bisphenol A Exposure Changes the Transcriptomic and Proteomic Dynamics of Human Retinoblastoma Y79 Cells. Genes (Basel). 2021 Feb 11;12(2):264. doi: 10.3390/genes12020264.
• [295] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [296] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [297] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [298] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [299] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [300] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [301] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [302] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [303] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [304] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [305] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [306] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [307] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [308] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [309] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [310] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [311] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [312] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [313] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [314] Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine. Eur J Nutr. 2006 Mar;45(3):159-64. doi: 10.1007/s00394-005-0576-5. Epub 2005 Dec 20.
• [315] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [316] Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway. J Toxicol Sci. 2015 Feb;40(1):127-36. doi: 10.2131/jts.40.127.
• [317] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [318] Bisphenol-A and estradiol exert novel gene regulation in human MCF-7 derived breast cancer cells. Mol Cell Endocrinol. 2004 Jun 30;221(1-2):47-55. doi: 10.1016/j.mce.2004.04.010.
• [319] Benzo[a]pyrene increases the Nrf2 content by downregulating the Keap1 message. Toxicol Sci. 2010 Aug;116(2):549-61.
• [320] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [321] Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56.
• [322] Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
• [323] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [324] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [325] Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes. Chem Res Toxicol. 2017 Oct 16;30(10):1847-1854. doi: 10.1021/acs.chemrestox.7b00171. Epub 2017 Sep 13.
• [326] Differential effects of omega-3 and omega-6 Fatty acids on gene expression in breast cancer cells. Breast Cancer Res Treat. 2007 Jan;101(1):7-16. doi: 10.1007/s10549-006-9269-x. Epub 2006 Jul 6.
• [327] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [328] Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia. Int J Oncol. 2005 Aug;27(2):537-45.
• [329] Effect of chemical mutagens and carcinogens on gene expression profiles in human TK6 cells. PLoS One. 2012;7(6):e39205. doi: 10.1371/journal.pone.0039205. Epub 2012 Jun 18.
• [330] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [331] Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009 Mar;144(5):667-76. doi: 10.1111/j.1365-2141.2008.07504.x. Epub 2008 Nov 20.
• [332] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [333] Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
• [334] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [335] Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
• [336] Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
• [337] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [338] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [339] Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem. 2011 Feb 25;286(8):6602-13.
• [340] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [341] Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer. 2008 Apr 1;122(7):1645-56. doi: 10.1002/ijc.23280.
• [342] Effects of folate deficiency on gene expression in the apoptosis and cancer pathways in colon cancer cells. Carcinogenesis. 2006 May;27(5):916-24. doi: 10.1093/carcin/bgi312. Epub 2005 Dec 16.
• [343] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [344] Changes in gene expressions elicited by physiological concentrations of genistein on human endometrial cancer cells. Mol Carcinog. 2006 Oct;45(10):752-63.
• [345] Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
• [346] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [347] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [348] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [349] The PPAR gamma agonist troglitazone induces musclin mRNA expression in human myotubes. Horm Metab Res. 2006 Sep;38(9):614-6. doi: 10.1055/s-2006-951310.
• [350] Retinoic acids and trichostatin A (TSA), a histone deacetylase inhibitor, induce human pyruvate dehydrogenase kinase 4 (PDK4) gene expression. Biochim Biophys Acta. 2006 Mar-Apr;1759(3-4):141-51. doi: 10.1016/j.bbaexp.2006.04.005. Epub 2006 Apr 27.
• [351] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [352] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [353] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [354] Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.
• [355] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [356] Characterization of the Molecular Alterations Induced by the Prolonged Exposure of Normal Colon Mucosa and Colon Cancer Cells to Low-Dose Bisphenol A. Int J Mol Sci. 2022 Oct 1;23(19):11620. doi: 10.3390/ijms231911620.
• [357] Gene expression changes in primary human nasal epithelial cells exposed to formaldehyde in vitro. Toxicol Lett. 2010 Oct 5;198(2):289-95.
• [358] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [359] Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013 Feb;45(2):145-54. doi: 10.1038/ng.2500. Epub 2012 Dec 23.
• [360] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [361] Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
• [362] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [363] Cystathionine metabolic enzymes play a role in the inflammation resolution of human keratinocytes in response to sub-cytotoxic formaldehyde exposure. Toxicol Appl Pharmacol. 2016 Nov 1;310:185-194.
• [364] Riboflavin depletion impairs cell proliferation in adult human duodenum: identification of potential effectors. Dig Dis Sci. 2011 Apr;56(4):1007-19. doi: 10.1007/s10620-010-1374-3. Epub 2010 Sep 17.
• [365] Effect of prenatal arsenic exposure on DNA methylation and leukocyte subpopulations in cord blood. Epigenetics. 2014 May;9(5):774-82. doi: 10.4161/epi.28153. Epub 2014 Feb 13.
• [366] A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling. PLoS One. 2017 May 25;12(5):e0178302. doi: 10.1371/journal.pone.0178302. eCollection 2017.
• [367] Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. Food Chem Toxicol. 2020 Feb;136:111047. doi: 10.1016/j.fct.2019.111047. Epub 2019 Dec 12.
• [368] Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ. 2000 Jun;7(6):574-86. doi: 10.1038/sj.cdd.4400688.
• [369] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [370] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [371] Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 2003 Feb 1;63(3):616-20.
• [372] Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets. Transplantation. 2002 Oct 27;74(8):1063-9. doi: 10.1097/00007890-200210270-00001.
• [373] Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem. 2010 Nov;344(1-2):173-84. doi: 10.1007/s11010-010-0540-4. Epub 2010 Jul 25.
• [374] Down regulation of N-acetylglucosaminyltransferase V facilitates all-transretinoic acid to induce apoptosis of human hepatocarcinoma cells. Mol Cell Biochem. 2006 Mar;284(1-2):103-10. doi: 10.1007/s11010-005-9022-5. Epub 2006 Jan 13.
• [375] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [376] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [377] Arsenic alters transcriptional responses to Pseudomonas aeruginosa infection and decreases antimicrobial defense of human airway epithelial cells. Toxicol Appl Pharmacol. 2017 Sep 15;331:154-163.
• [378] NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
• [379] Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
• [380] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [381] Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
• [382] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [383] Characterizing the genetic basis for nicotine induced cancer development: a transcriptome sequencing study. PLoS One. 2013 Jun 18;8(6):e67252.
• [384] Effect of mood stabilizers on gene expression in lymphoblastoid cells. J Neural Transm (Vienna). 2010 Feb;117(2):155-64.
• [385] Highly conserved mouse and human brain sulfotransferases: molecular cloning, expression, and functional characterization. Gene. 2002 Feb 20;285(1-2):39-47. doi: 10.1016/s0378-1119(02)00431-6.
• [386] Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS One. 2011;6(11):e27484.
• [387] Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease. Metabolism. 1997 Oct;46(10):1184-8. doi: 10.1016/s0026-0495(97)90214-6.
• [388] Long-term efficacy and tolerability of octreotide treatment in acromegaly. Metabolism. 1992 Sep;41(9 Suppl 2):44-50. doi: 10.1016/0026-0495(92)90030-e.
• [389] Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo. Clin Neuropharmacol. 1996 Feb;19(1):72-80. doi: 10.1097/00002826-199619010-00006.
• [390] Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation. 1991 Aug;84(2):550-7. doi: 10.1161/01.cir.84.2.550.
• [391] Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients--a pilot study. Anticancer Res. 2007 Jul-Aug;27(4A):1883-6.
• [392] Goitrogenic anions, thyroid-stimulating hormone, and thyroid hormone in infants. Environ Health Perspect. 2010 Sep;118(9):1332-7. doi: 10.1289/ehp.0901736. Epub 2010 Apr 27.
• [393] Enhanced photodynamic effect of cobalt(III) dipyridophenazine complex on thyrotropin receptor expressing HEK293 cells. Metallomics. 2010 Nov;2(11):754-65. doi: 10.1039/c0mt00028k. Epub 2010 Oct 21.
• [394] Thyroid organotypic rat and human cultures used to investigate drug effects on thyroid function, hormone synthesis and release pathways. Toxicol Appl Pharmacol. 2012 Apr 1;260(1):81-8. doi: 10.1016/j.taap.2012.01.029. Epub 2012 Feb 8.
• [395] Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
• [396] Screening the ToxCast Phase 1, Phase 2, and e1k Chemical Libraries for Inhibitors of Iodothyronine Deiodinases. Toxicol Sci. 2019 Apr 1;168(2):430-442. doi: 10.1093/toxsci/kfy302.
• [397] Effects of all-trans and 9-cis retinoic acid on differentiating human neural stem cells in vitro. Toxicology. 2023 Mar 15;487:153461. doi: 10.1016/j.tox.2023.153461. Epub 2023 Feb 16.
• [398] Regulation of type 1 iodothyronine deiodinase in health and disease. Thyroid. 2005 Aug;15(8):835-40. doi: 10.1089/thy.2005.15.835.
• [399] Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.